Orelabrutinib, fludarabine, cyclophosphamide, and obinutuzumab (OFCG) for first-line treatment of chronic lymphocytic leukemia: a multicenter phase II trial (cwCLL-001 trial)
Elsevier ·
Аннотация у издателя не опубликована — полный текст доступен по ссылке ниже.
Orelabrutinib, fludarabine, cyclophosphamide, and obinutuzumab (OFCG) for first-line treatment of chronic lymphocytic leukemia: a multicenter phase II trial (cwCLL-001 trial). // Journal of the National Cancer Center. – URL: https://www.sciencedirect.com/science/article/pii/S2667005426000554?dgcid=rss_sd_all
Orelabrutinib, fludarabine, cyclophosphamide, and obinutuzumab (OFCG) for first-line treatment of chronic lymphocytic leukemia: a multicenter phase II trial (cwCLL-001 trial). Journal of the National Cancer Center. https://www.sciencedirect.com/science/article/pii/S2667005426000554?dgcid=rss_sd_all
“Orelabrutinib, fludarabine, cyclophosphamide, and obinutuzumab (OFCG) for first-line treatment of chronic lymphocytic leukemia: a multicenter phase II trial (cwCLL-001 trial).” Journal of the National Cancer Center.
@article{article55765,
title = {Orelabrutinib, fludarabine, cyclophosphamide, and obinutuzumab (OFCG) for first-line treatment of chronic lymphocytic leukemia: a multicenter phase II trial (cwCLL-001 trial)},
journal = {Journal of the National Cancer Center},
url = {https://www.sciencedirect.com/science/article/pii/S2667005426000554?dgcid=rss_sd_all}
}